Navigation Links
Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
Date:12/10/2007

as "may," "believe," "provide," "potential," "planning" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current plans, assumptions, beliefs and expectations. Forward-looking statements involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the potential failure of our product candidates to demonstrate safety and efficacy in clinical testing; the ability to initiate and complete trials at the referenced times; the ability to conduct clinical trials sufficient to achieve a positive completion; the uncertainty of the FDA approval process; the therapeutic and commercial value of our compounds and risks related to our need for additional financing. These and other risk factors are discussed under "Risk Factors" and elsewhere in our quarterly report on Form 10-Q for the quarter ended September 30, 2007 and our other filings with the Securities and Exchange Commission. We expressly disclaim any duty, obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
10. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
11. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... , Nov. 28, 2014 Aratana Therapeutics, Inc. (NASDAQ: ... on the licensing or acquisition, development and commercialization of ... animals, today announced that it will present at the ... be held December 2-3, 2014, at the New York ... Steven St. Peter , M.D., President ...
(Date:11/28/2014)... , Nov. 28, 2014 Chinese magnesium alloy ... that its biodegradable magnesium alloy bone fixation screw has ... medical apparatus and instrument and that the company ... an interview with Science and Technology Daily ... the company chairman and founder, Professor Li Yangde ...
(Date:11/27/2014)... 2014 Hovione announced today it ... with the U.S. Food and Drug Administration (FDA). This ... improved drug delivery options for established drugs. ... formulation using a new patented crystalline base form of ... prescribed oral antibiotics for acne. Currently, there are no ...
Breaking Medicine Technology:Aratana Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Chinese magnesium alloy manufacturer Eontec expects to have its medical magnesium alloy available for clinical trial in 2015 2Chinese magnesium alloy manufacturer Eontec expects to have its medical magnesium alloy available for clinical trial in 2015 3Chinese magnesium alloy manufacturer Eontec expects to have its medical magnesium alloy available for clinical trial in 2015 4Hovione Files its First Investigational New Drug Application With the FDA 2
... The U.S.-Russia Business Council is pleased to announce that General ... two new joint ventures in Russia. These joint ventures bolster ... enhancing Russia,s power generation and healthcare sectors. ... – 15 billion in sales, GE will sell at least ...
... Medical Imaging of Fredericksburg is one of ...  Best of 2011 Radiology Facilities issue, a ... In an article titled "Small Town ... Imaging of Fredericksburg, a partnership between Mary Washington ...
Cached Medicine Technology:USRBC President Ed Verona Lauds GE Announcement on Energy and Healthcare Joint Ventures in Russia 2Medical Imaging of Fredericksburg Highlighted in Imaging Economics' Best of 2011 Radiology Facilities Issue 2
(Date:11/28/2014)... 28, 2014 Dr. Diane Walder, one of ... new treatment to her practice called Ultrashape that is designed ... three inches in just six weeks. Ultrashape has been praised ... superior in results when compared to other types of external ... treat it,” said Dr. Walder. , According to Dr. ...
(Date:11/28/2014)... 28, 2014 The Alternative ... over the past five years. The industry has ... therapies that are either alternative to conventional Western ... IBISWorld industry analyst David Whytcross, “industry revenue has ... growing private health insurance membership.” Meanwhile, improving economic ...
(Date:11/28/2014)... THURSDAY, Nov. 27, 2014 (HealthDay News) -- Celebration ... are misused on Thanksgiving Day, experts say. Over ... hot-oil burns have occurred while people were using turkey ... "I have actually cared for a patient who ... should not be done in any circumstances," Dr. Arthur ...
(Date:11/28/2014)... 28, 2014 Not only is the ... free of petroleum, parabens and other cancer-causing agents, but ... research, education and awareness programs that help in the ... owners have raised an incredible, record-breaking contribution of $30,000 ... sales of the Sweet Red Rose Whip Moisturizer and ...
(Date:11/28/2014)... CA (PRWEB) November 28, 2014 ... online, reported during the hugely popular, 2014 MTV ... antismoking organization Truth launched ground-breaking celebrity centered television ... The MTV viewership figures were estimated by ... antismoking ads placed the spotlight on celebrities photographed ...
Breaking Medicine News(10 mins):Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5
... scientists from Iowa and Iran have discovered a new strategy ... rejected by a recipient,s immune system. This strategy, described in ... issue of The FASEB Journal ( http://www.fasebj.org ), ... fused, the hybrid cells have DNA from both the donor ...
... new treatment that could one day benefit burns victims, ... the healing of chronic wounds has taken another ... Cowin, from the Women,s and Children,s Health Research Institute ... of Surgery , has today received a $529,450 Development ...
... ... economic ups and downs of the decade. , ... Pennington, NJ (PRWEB) January 28, 2010 -- In good times and in ... Gallup & Robinson, Inc., overall attitudes towards Super Bowl advertising have remained strongly positive throughout ...
... number of injured calls for specialized pediatric care, researchers ... Children are likely to account for about 44 percent ... devastating Jan. 12 earthquake -- information that could be ... statistical study by the team at Children,s Hospital Los ...
... , NEW YORK , ... PricewaterhouseCoopers LLP Manufacturing Barometer reports cautious optimism about the U.S. ... 2009 report. Nearly half (47 percent) of survey respondents are optimistic ... a year ago.  Similarly, 41 percent of panelists who sell internationally ...
... survey results indicate ,having work done, not taboo anymore ... surgery is everywhere these days: TV, magazines, the Internet and ... comfortable talking about cosmetic surgery than ever before. , In ... Surgery, 71 percent of respondents think society is less judgmental ...
Cached Medicine News:Health News:Stem cell breakthrough: Bone marrow cells are the answer 2Health News:Wound treatment wins commercialization funds 2Health News:Super Bowl Advertising, In Good Times And Bad 2Health News:Super Bowl Advertising, In Good Times And Bad 3Health News:Haitian Children Need Specific Relief Efforts 2Health News:Cautious Optimism Begins, Pessimism Declines on U.S. and Global Economies Among U.S. Industrial Manufacturers, According to PricewaterhouseCoopers' Q4 2009 Manufacturing Barometer 2Health News:Cautious Optimism Begins, Pessimism Declines on U.S. and Global Economies Among U.S. Industrial Manufacturers, According to PricewaterhouseCoopers' Q4 2009 Manufacturing Barometer 3Health News:Cautious Optimism Begins, Pessimism Declines on U.S. and Global Economies Among U.S. Industrial Manufacturers, According to PricewaterhouseCoopers' Q4 2009 Manufacturing Barometer 4Health News:Cautious Optimism Begins, Pessimism Declines on U.S. and Global Economies Among U.S. Industrial Manufacturers, According to PricewaterhouseCoopers' Q4 2009 Manufacturing Barometer 5Health News:Cautious Optimism Begins, Pessimism Declines on U.S. and Global Economies Among U.S. Industrial Manufacturers, According to PricewaterhouseCoopers' Q4 2009 Manufacturing Barometer 6Health News:Society More Open Than Ever About Cosmetic Surgery 2
... Captique is a non-animal stabilized ... newest HA filler to enter the ... correction of moderate to severe facial ... folds). Captique is injected just under ...
... Radiesse brings you into the new age ... now offer your patients immediate, long-term results ... flexibility. This injectable filler offers superior versatility ... and reconstructive treatments. Long-lasting, Radiesse saves time ...
The HEMOCHRON Model 401 is a portable, single-well whole blood coagulation monitoring instrument. The 401 provides on-screen plasma equivalent PT and APTT test results....
... proven to reduce the appearance of cellulite ... combines Retinol, the purest form of Vitamin ... works deep within skin's surface to improve ... Fast absorbing, it has a fresh, clean ...
Medicine Products: